P
0.863
0.08 (10.07%)
| 前收盘价格 | 0.784 |
| 收盘价格 | 0.794 |
| 成交量 | 991,940 |
| 平均成交量 (3个月) | 560,777 |
| 市值 | 98,146,464 |
| 价格/销量 (P/S) | 0.550 |
| 股市价格/股市净资产 (P/B) | 1.03 |
| 52周波幅 | |
| 利润日期 | 7 Aug 2023 - 11 Aug 2023 |
| 营业毛利率 | 10.43% |
| 营业利益率 (TTM) | -3,894.36% |
| 稀释每股收益 (EPS TTM) | 1.04 |
| 季度收入增长率 (YOY) | -95.60% |
| 总债务/股东权益 (D/E MRQ) | 53.28% |
| 流动比率 (MRQ) | 6.34 |
| 营业现金流 (OCF TTM) | -58.45 M |
| 杠杆自由现金流 (LFCF TTM) | -2.34 M |
| 资产报酬率 (ROA TTM) | -11.04% |
| 股东权益报酬率 (ROE TTM) | 19.05% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Precision BioSciences, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
1.1
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | 3.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 0.0 |
| 平均 | 1.13 |
|
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 9.40% |
| 机构持股比例 | 46.49% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Lynx1 Capital Management Lp | 31 Dec 2024 | 766,051 |
| Aquilo Capital Management, Llc | 31 Dec 2024 | 536,376 |
| 52周波幅 | ||
| 中 | 60.00 (6,856.52%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 28 Mar 2025 | 60.00 (6,856.52%) | 购买 | 4.70 |
| 19 Mar 2025 | 60.00 (6,856.52%) | 购买 | 5.01 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合